Anti-Human IL-23 (Guselkumab) (I-2150-1.0mg)

IL-23 is a member of the IL-12 family of proinflammatory and immunoregulatory cytokines1 and plays a key role in the differentiation and proliferation of type 17 helper T cells (Th17)2. IL- 23 exists as a heterodimer composed of the IL-12p40 subunit and a novel p19 subunit that is shared with IL-393. IL-23 activities lead to the production of Th17-derived pro-inflammatory cytokines IL-17 and IL-221. Additionally, IL-23 possesses potent anti-tumor and anti-metastatic activity in mouse models of cancer, suggesting a potential role for IL-23 in therapeutic treatment of cancer4. IL-23 also contributes to chronic inflammation of immune-mediated diseases including psoriasis and psoriatic arthritis2. Guselkumab was developed using MorphoSys proprietary HuCAL ® antibody library technology2 to explore IL-23 blockade without interfering with IL-12 activity5. Guselkumab inhibits the biological activity of secreted IL-23 by preventing IL-23 from binding to cell surface receptors and consequently blocking the initiation of IL-23-receptor-mediated signaling. Guselkumab has been approved for treatment of psoriasis and psoriatic arthritis. Guselkumab is also being tested for the treatment of ulcerative colitis6.